Phase 3 Clinical Trials With Primary Completion Dates in July 2022
This is a list of Phase 3 trials with primary completion dates in July 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AEZS | Aeterna Zentaris Inc. | 2022-07-01 | Phase 3 | NCT04786873 | A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is |
| ALLK | Allakos Inc. | 2022-07-01 | Phase 3 | NCT04856891 | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis |
| ARDS | Aridis Pharmaceuticals, Inc. | 2022-07-01 | Phase 3 | NCT03816956 | Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 |
| CORT | Corcept Therapeutics Incorporated | 2022-07-01 | Phase 3 | NCT04308590 | Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas |
| INO | Inovio Pharmaceuticals, Inc. | 2022-07-01 | Phase 3 | NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) |
| ISEE | IVERIC bio, Inc. | 2022-07-01 | Phase 3 | NCT04435366 | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) |
| KOD | Kodiak Sciences Inc. | 2022-07-01 | Phase 3 | NCT04592419 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) |
| MOLN | Molecular Partners AG | 2022-07-01 | Phase 3 | NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 |
| NEPH | Nephros, Inc. | 2022-07-01 | Phase 3 | NCT04591015 | Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19 |
| NEPH | Nephros, Inc. | 2022-07-01 | Phase 3 | NCT04459338 | A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion |
| ONPH | Oncology Pharma Inc. | 2022-07-01 | Phase 3 | NCT02819960 | Prevention of Irinotecan Induced Diarrhea by Probiotics |
| SYNH | Syneos Health, Inc. | 2022-07-01 | Phase 3 | NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| TEVA | Teva Pharmaceutical Industries Limited | 2022-07-01 | Phase 3 | NCT02688140 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia |
| TEVA | Teva Pharmaceutical Industries Limited | 2022-07-01 | Phase 3 | NCT03813238 | A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
| VAXX | Vaxxinity, Inc. | 2022-07-01 | Phase 3 | NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| VIR | Vir Biotechnology, Inc. | 2022-07-01 | Phase 3 | NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 |
| VNDA | Vanda Pharmaceuticals Inc. | 2022-07-01 | Phase 3 | NCT05361707 | Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances |
| XRAY | DENTSPLY SIRONA Inc. | 2022-07-01 | Phase 3 | NCT04082143 | CATER: Comprehensive Alveolar and Tooth Esthetic Replacement |